Are Robots More Dangerous Than Cholesterol? No.

In this episode we dive deep into new technologies in the ongoing attempt to get cholesterol levels under control worldwide. Heart disease remains the #1 killer in America, and much of the blame falls on high cholesterol. We go into what cholesterol is and some of the new targets and technologies being developed now to help keep the body in line producing the right amount of the right proteins for good cholesterol control.References:Occupational Safety and Health Administration. (2025). Accident search results: Keyword “Robot”. U.S. Department of Labor. Accessed 3 September, 2025. https://www.osha.gov/ords/imis/AccidentSearch.search?acc_keyword=%22Robot%22&keyword_list=on&Fatal=fatalU.S.Centers for Disease Control and Prevention. (2019). Leading causes of death, 1900-1998. U.S. Department of Health and Human Services. https://archive.cdc.gov/www_cdc_gov/nchs/data/dvs/lead1900_98.pdfMurphy, S. L., Kochanek, K. D., Xu, J., & Arias, E. (2024). Mortality in the United States, 2023. In NCHS Data Briefs [Internet]. National Center for Health Statistics (US). https://www.cdc.gov/nchs/products/databriefs/db521.htmMakhmudova, U., Steinhagen-Thiessen, E., Volpe, M., & Landmesser, U. (2024). Advances in nucleic acid-targeted therapies for cardiovascular disease prevention. Cardiovascular Research, 120(10), 1107-1125. https://doi.org/10.1093/cvr/cvae136O'Donoghue, M. L., López, J. A. G., Knusel, B., Gencer, B., Wang, H., Wu, Y., ... & Sabatine, M. S. (2022). Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE). American Heart Journal, 251, 61-69. https://www.sciencedirect.com/science/article/pii/S0002870322000862Nissen, S. E., Wolski, K., Cho, L., Nicholls, S. J., Kastelein, J., Leitersdorf, E., ... & Nordestgaard, B. G. (2022). Lipoprotein (a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart, 9(2), e002060. https://openheart.bmj.com/content/9/2/e002060Damase, T. R., Sukhovershin, R., Godin, B., Nasir, K., & Cooke, J. P. (2024). Established and emerging nucleic acid therapies for familial hypercholesterolemia. Circulation, 150(9), 724-735. https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.123.067957Oral, E. A., Garg, A., Tami, J., Huang, E. A., O'Dea, L. S. L., Schmidt, H., ... & Tsimikas, S. (2022). Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study. Journal of Clinical Lipidology, 16(6), 833-849.Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., ... & Yataco, A. (2021). Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The lancet Diabetes & endocrinology, 9(5), 264-275.Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., ... & Sabatine, M. S. (2024). Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. New England Journal of Medicine, 390(19), 1770-1780.<Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedInTiktokYoutubeFor more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! Podcast and MedEvidence.comThank you for listening!